Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The trial ...
Indian scientist Dr. Nageswara Rao Kalikinidi, Senior Principal Scientist at TCG GreenChem, Inc., New Jersey, USA, is gaining ...
AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...
Roche ( RHHBF) ( RHHBY) shares fell after the Swiss drugmaker’s investigational breast cancer pill failed to meet the primary goal of a late-stage breast cancer trial.
Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset ...
The study did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a ...
Roche’s phase III persevERA Breast Cancer study of giredestrant in combo with palbociclib ER-positive advanced breast cancer fails to meet its primary objective: Basel Tuesday, ...
ERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observedGiredestrant plus ...
The randomized, double-blind, placebo-controlled, multicenter study enrolled 992 patients globally. The intent-to-treat ...
ERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbocicl ...
Clinical Trials Arena on MSN
Roche’s oral SERD fails in Phase III breast cancer trial
In the study, giredestrant showed no statistical improvement in the primary endpoint, but there was a numerical improvement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results